The Naval Medical Research Center (NMRC) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) recently established an agreement with Lumen Bioscience, located in Seattle, to develop a new immunotherapy to prevent gastrointestinal diseases caused by Campylobacter jejuni and enterotoxigenic E. coli (ETEC).
3M Health Care launched 3M™ Polisher™ ST,* an advanced, single-use AEX solution designed to replace reusable AEX polishing column for biologic drug manufacturing.
Caliper Ingredients (Caliper), a leading manufacturer and supplier of soluble cannabinoid ingredients, in conjunction with Colorado State University (CSU), has completed the CBD industry's first human clinical study of commercially available CBD-infused food and supplement product pharmacokinetics.
Pharmacists & technicians at Precision LTC Pharmacy conducted a seamless distribution of the Moderna COVID-19 vaccine to over 200 individuals & staff from Maryhaven Center of Hope last Wednesday.
Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Phase 2 clinical trial and signed first agreement in global licensing progress. GoldenBiotech receives in Jan.
Chengdu Kanghong Pharmaceutical Group ("Kanghong", SHE: 002773), has received Special Protocol Assessments from the Food and Drug Administration for three new indications for its biologic drug conbercept. The drug is an anti-VEGF fusion protein, approved and marketed in China as Lumitin®, for the treatment of retinal diseases.
The Feinstein Institutes for Medical Research and Cold Spring Harbor Laboratory (CSHL) are recruiting patients in a fully virtual, in-home, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of famotidine, or PEPCID, for the outpatient treatment of the novel coronavirus disease 2019 (COVID-19) in adults.
As COVID-19 continues to impact every aspect of the healthcare and financial sectors, consumers around the country are confronting an uncertain economic climate while also addressing some familiar challenges—including the ever-increasing cost of prescription drugs.
Prism Health Lab - a branch of the 30+-year-old Prism Group of Companies - has launched its sixth location in as many months in the Chinatown neighborhood of Chicago by leveraging Prism's unique digital technology developed to enable large scale and cost-effective testing.
OpenEye Scientific and Sygnature Discovery – a world-leading integrated discovery and pre-clinical solutions provider – today announced the adoption of OpenEye's Orion™ platform to power Sygnature's computational efforts in molecular design drug discovery solutions.